Response to ‘Ultrasound surveillance and graft patency’  by Robbin, M.L. & Allon, M.
There are several differences in the study design that could
theoretically explain contradictory results.
Robbin et al.1 included subjects later after surgery – the
mean graft age was 9 months at inclusion, while we performed
inclusion and first ultrasound examination within 4 weeks
after access creation. We could hypothesize that high-risk
grafts, which thrombose within first year after access creation,
were therefore not included into Robbin’s study. Such patients
probably profit from ultrasound surveillance most.
Another difference is that although Robbin et al.1
performed a single-center study, our patients were hemodia-
lyzed in 25 centers. Although all dialysis centers in our study
made every effort to follow K/Dialysis Outcome Quality
Initiative guidelines, their experience could vary. Access flow
was monitored in less than 50% of patients in our study.
These factors could increase the profit of ultrasound
surveillance in our study. We think that multi-center study
reflects better routine care, which is probably less perfect than
in highly specialized hemodialysis units of university
hospitals. On the contrary, in the light of Dossabhoy’s study,
higher use of access flow monitoring would probably not
change dramatically our results.
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We thank Dr Malik1 for his interest. Our average graft age
at enrollment was 8.877.3 months,2 whereas Malik’s
patients were enrolled by 1 month.3 Malik’s study showed
a significant difference between control and ultrasound
group by 6 months of graft age. We potentially did not
enroll some problematic grafts that failed by 6–9 months.
However, 27% of our grafts had a prior thrombectomy, and
33% had a prior percutaneous transluminal angioplasty.
Furthermore, our subgroup analysis of 57 ‘virgin’ grafts
(45%) showed no significant difference in time to graft
failure or thrombosis-free survival between the ultrasound
and control group. Thus, the difference between the study
results is unlikely to be owing to graft age at enrollment.
Additionally, even after 9 months, Malik’s data show a
continued steep decline in the access patency of control
group grafts, not demonstrated in our data.
Our data represent five University of Alabama centers
with fairly uniform graft assessments. Practice patterns may
differ more widely between the 25 centers in Malik’s study.
Access flow was monitored in about 50% of the control
patients in Malik’s study. We performed comparable
routine graft clinical monitoring, but did not perform
access flow, dynamic pressure, or recirculation measure-
ments. The study differences may be due, in part, to our
more frequent routine clinical monitoring. Angioplasty
versus thrombectomy frequencies for Malik’s groups
would be useful in this assessment.
Ultrasound can detect graft stenoses that are not
clinically significant.4 However, no benefit of pre-emptive
angioplasty in clinically asymptomatic stenoses was
demonstrated in our study.
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To the Editor: We read with great interest the recent paper by
Suissa et al.1 The authors found that the use of angiotensin-
converting enzyme inhibitors (ACEI) by patients with
diabetes was not associated with long-term decreased risk
of renal failure. Their findings suggested instead a higher risk
of renal failure in those who took ACEI, even after having
adjusted for other risk factors.
In our previous publication,2 where we reported that
ACEI/angiotensin II receptor antagonist (ATRA) therapy
decreases proteinuria by improving glomerular permselec-
tivity in IgA nephritis, we found ATRA to be superior. Our
data showed that majority of the non-responders were on
ACEI compared to the responders who were on ATRA
(w2¼ 6.3, Po0.02; Table 1a), suggesting that ATRA is more
effective in decreasing proteinuria. In this respect, we are not
surprised by the data of Suissa et al.,1 who showed that ACEI
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